ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

The Royal Marsden at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

The Royal Marsden takes part in 39 sessions at ESMO 2026 in Madrid. Its program spans treatment and supportive care across cancer types, with attention to biomarkers and precision oncology. It explores how shared and tumour-specific neoantigens can help select T-cell receptors.

OrganizationESMO 2026 Attendance
The Royal Marsden
London, United Kingdom
Cancer centre & hospital
NHS specialist cancer hospital with sites in London and Sutton, England, partnered with the Institute of Cancer Research.
Poster
Fri Oct 23
13:00–15:00
Eltrombopag for chemotherapy-induced thrombocytopenia (CIT) in advanced gastrointestinal (GI) cancers: A retrospective analysis
ePoster session 5
Gastrointestinal cancersNursing & supportive care
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Supportive oncology for patients with malignant melanoma: A service evaluation
ePoster session 16
Melanoma & skin cancersNursing & supportive care
Poster
Fri Oct 23
13:00–15:00
Transforming supportive care for people living with lung cancer who have never smoked
ePoster session 21
Lung & thoracic cancersNursing & supportive care
Chair
Fri Oct 23
13:30–15:00
Melanoma: From standard fit to bespoke care
with University of Colorado Anschutz Medical Campus
Melanoma & skin cancers
Chair
Fri Oct 23
13:30–15:00
Rapid oral: Genitourinary tumours, prostate, penile and testis
with Brigham and Women's Hospital, Monash University
Genitourinary cancersGastrointestinal cancers
Abstract
Fri Oct 23
13:45–13:57
Invited Discussant 1209RO, 1210RO and 2217RO
Rapid oral: Genitourinary tumours, prostate, penile and testis
Genitourinary cancersGastrointestinal cancers
Talk
Fri Oct 23
13:50–14:10
Shared and private neoantigen selection: Matchmaking TCRs
Melanoma: From standard fit to bespoke care
Melanoma & skin cancers
Chair
Fri Oct 23
15:15–16:00
Chair
Fri Oct 23
16:15–17:45
Ensuring compassionate integrated palliative and oncology care: Best practices, approaches, and decision-making
with University Medical Center Groningen
Nursing & supportive care
Talk
Fri Oct 23
16:15–16:20
Introduction
Ensuring compassionate integrated palliative and oncology care: Best practices, approaches, and decision-making
Nursing & supportive care
Abstract
Fri Oct 23
17:00–17:10
Talk
Fri Oct 23
17:10–17:25
DC programme overview: Where we are and where we are going
Ensuring compassionate integrated palliative and oncology care: Best practices, approaches, and decision-making
Nursing & supportive care
Chair
Sat Oct 24
10:15–11:45
ESMO Clinical Practice Guidelines 1
with Odense University Hospital
Gastrointestinal cancersGynaecological cancers
Chair
Sat Oct 24
10:15–11:30
Multidisciplinary insights for effective care in gynaecological sarcomas
with Netherlands Cancer Institute
Sarcoma, CNS, head & neck and rare cancers
Talk
Sat Oct 24
10:15–10:20
Presentation of case/condition
Multidisciplinary insights for effective care in gynaecological sarcomas
Sarcoma, CNS, head & neck and rare cancers
Abstract
Sat Oct 24
11:20–11:32
Invited Discussant LBA53 and 2045O
Proffered paper: Genitourinary tumours, prostate, penile and testis
Genitourinary cancers
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
Breast cancer leptomeningeal disease, have we improved? A 20-year single centre-experience
Saturday Poster Display session 1
Breast cancerSarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
13:10–13:20
Impact of Peri operative IO in LA HNSCC: From Biological Rationale to Clinical Outcomes
MSD - Practical MDT Considerations for the new Treatment Paradigm in Resectable LA HNSCC
Sarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
13:40–14:10
MDT Case Discussion
MSD - Practical MDT Considerations for the new Treatment Paradigm in Resectable LA HNSCC · with Lausanne University Hospital (CHUV), Dana-Farber Cancer Institute, Hospital Universitario Fundación Jiménez Díaz
Sarcoma, CNS, head & neck and rare cancers
Abstract
Sat Oct 24
15:05–15:17
Invited Discussant LBA89 and 3715O
Proffered paper: Sarcoma
Sarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
18:30–18:35
Welcome and Introduction
Medscape Global Oncology - Beyond Chemotherapy: Integrating Novel Targeted Agents Into Platinum-Resistant Ovarian Cancer Clinical Practice
Gynaecological cancers
Satellite
Sat Oct 24
19:15–19:35
Precision in Practice – Navigating Biomarkers and Sequencing
Medscape Global Oncology - Beyond Chemotherapy: Integrating Novel Targeted Agents Into Platinum-Resistant Ovarian Cancer Clinical Practice
Gynaecological cancers
Satellite
Sat Oct 24
19:35–19:50
Future Directions and Case-Based Application
Medscape Global Oncology - Beyond Chemotherapy: Integrating Novel Targeted Agents Into Platinum-Resistant Ovarian Cancer Clinical Practice · with Medical University of Innsbruck, European Institute of Oncology (IEO)
Gynaecological cancers
Chair
Sun Oct 25
08:30–10:00
Proffered paper: Head and neck cancer
with Attikon University Hospital
Sarcoma, CNS, head & neck and rare cancers
Abstract
Sun Oct 25
09:38–09:50
Invited Discussant LBA44, LBA45 and 1535O
Proffered paper: Head and neck cancer
Sarcoma, CNS, head & neck and rare cancers
Talk
Sun Oct 25
10:15–10:30
Black women's views and experiences of making lifestyle changes following breast cancer treatment
Equitable health care of underserved population
Nursing & supportive care
Chair
Sun Oct 25
10:15–11:45
ESMO Clinical Practice Guidelines 2
with Odense University Hospital
Breast cancerGenitourinary cancers
Chair
Sun Oct 25
10:15–11:15
Talk
Sun Oct 25
10:15–10:20
The ESMO Resilience Resource Hub: Next steps
Fostering resilience under fire: Sustaining motivation and meaning in oncology
Talk
Sun Oct 25
11:05–11:15
Poster
Sun Oct 25
12:00–12:45
Does Europe still generate its own evidence? Patient enrollment in pivotal trials for EMA solid tumour approvals, 2020-2025
Sunday Poster Display session 5
Gastrointestinal cancersGynaecological cancersLung & thoracic cancersGenitourinary cancers
Poster
Sun Oct 25
12:00–12:45
Pan-cancer clinico-genomic machine learning for survival prediction following immune checkpoint inhibitor therapy
Sunday Poster Display session 1
Biomarkers & precision oncology
Poster
Sun Oct 25
12:00–12:45
The clinical landscape of HER2-low gastro-oesophageal adenocarcinoma: A Royal Marsden real-world cohort
Sunday Poster Display session 3
Gastrointestinal cancers
Satellite
Sun Oct 25
13:00–13:05
Welcome and introduction
F. Hoffmann - La Roche LTD - Next-era strategies in HR+ HER2– early breast cancer: Optimising endocrine therapy
Breast cancer
Satellite
Sun Oct 25
13:05–13:25
Current adjuvant endocrine-based therapies and unmet needs in patient care
F. Hoffmann - La Roche LTD - Next-era strategies in HR+ HER2– early breast cancer: Optimising endocrine therapy
Breast cancer
Chair
Sun Oct 25
14:45–16:15
Rapid oral 2: Genitourinary tumours, renal and urothelial
with University of Bari Aldo Moro, Ghent University Hospital
Genitourinary cancers
Abstract
Sun Oct 25
15:54–16:06
Invited Discussant 3593RO, 3594RO and 3595RO
Rapid oral 2: Genitourinary tumours, renal and urothelial
Genitourinary cancers
Chair
Sun Oct 25
16:30–18:00
Rapid oral: Supportive and palliative care
with MD Anderson Cancer Center, The University of Melbourne
Nursing & supportive care
Abstract
Sun Oct 25
17:45–17:55
Invited Discussant 3087RO, 3088RO, 3898RO
Rapid oral: Supportive and palliative care
Nursing & supportive care
Talk
Mon Oct 26
09:10–09:30
Clinical trials in rare tumors
YO Forum: Thinking beyond traditional research ideas
Poster
Mon Oct 26
12:00–12:45
Lanreotide in grade 2 GEP-NETs: Real-world efficacy according to Ki-67 index
Monday Poster Display session 3
Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45
Prognostic value of platelet-to-lymphocyte ratio in gastroenteropancreatic and pulmonary neuroendocrine tumours
Monday Poster Display session 3
Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersLung & thoracic cancers
Chair
Mon Oct 26
12:00–12:50
What oncologists should know about interpreting tumour sequencing
with LMU University Hospital Munich, Memorial Sloan Kettering Cancer Center
Biomarkers & precision oncology
Talk
Mon Oct 26
12:15–12:30
Liquid biopsy and CHIP: What clinicians need to know
What oncologists should know about interpreting tumour sequencing
Biomarkers & precision oncology
Satellite
Mon Oct 26
13:25–13:50
Real-world experience: Challenges & strategies in treating DTs
Merck Healthcare KGaA - CARE FOR RARE: Desmoid Tumours in Clinical Practice − Shifting Strategies & Evolving Perspectives · with Institut Bergonié
Sarcoma, CNS, head & neck and rare cancers
Chair
Mon Oct 26
14:45–16:15
Talk
Mon Oct 26
14:45–15:05
Introduction to the development of ESMO's CPG
How can the use of ESMO's Clinical Practice Guidelines (CPG) help drive standards of care?
Abstract
Mon Oct 26
15:43–15:53
2511O - Final analysis of adjuvant pembrolizumab (pembro) in resected early-stage non– small-cell lung cancer (NSCLC): Phase 3 PEARLS/KEYNOTE-091 study
Proffered paper: Non-metastatic NSCLC and other thoracic malignancies
Lung & thoracic cancers
Talk
Mon Oct 26
15:45–16:05
Local treatments for imatinib-resistant GIST: Implications of broad KIT inhibition
Optimising GIST management: From prognostic insights to new therapeutic strategies
Sarcoma, CNS, head & neck and rare cancers
Talk
Mon Oct 26
15:45–16:05
MRD to inform treatment decision
Incorporation of biomarkers for early breast cancer
Breast cancer
Chair
Tue Oct 27
09:00–13:00

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at The Royal Marsden

Tell us what you sell and we’ll find the people at The Royal Marsden most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction